Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Bionomics Ltd. (OTC: BNOEF).

Full DD Report for BNOEF

Recent News from (OTC: BNOEF)

OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market presenting companies at the 30 th Annual ROTH Confe...
Source: PR Newswire
Date: March, 08 2018 10:00
Bionomics NOW Newsletter February 2018
Bionomics NOW Newsletter February 2018
Source: OTC Markets
Date: February, 05 2018 00:00
Results of Meeting
Results of Meeting
Source: OTC Markets
Date: November, 15 2017 00:00
CEO & Managing Director's Report to Shareholders
CEO & Managing Director's Report to Shareholders
Source: OTC Markets
Date: November, 15 2017 00:00
Chairman's Address to Shareholders
Chairman's Address to Shareholders
Source: OTC Markets
Date: November, 15 2017 00:00
BNC101 Phase 1 Clinical Trial Recruitment Completed
BNC101 Phase 1 Clinical Trial Recruitment Completed
Source: OTC Markets
Date: October, 31 2017 00:00
Bionomics & MSD 5th Annual Neuroscience Symposium
Bionomics & MSD 5th Annual Neuroscience Symposium
Source: OTC Markets
Date: August, 21 2017 00:00
OTC Markets Group Announces Quarterly Index Performance and Rebalancing
NEW YORK , July 14, 2017 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced the second quarter 2017 performance and quarterly rebalancing of the OTCQX® and OTCQB® indexes, including the OTC...
Source: PR Newswire
Date: July, 14 2017 12:39
Bionomics: A Company With Deals On The Horizon
Ticker: BNOEF Share Price: ASX: A$0.395 OTCQX:US$.30 Market Capitalization: A190m Cash: A$50m Debt:US$15m Bionomics is an Australian clinical stage bio-pharmaceutical company that has focused on two scientific areas that present blockbuster drug opportunities for investors. Cen...
Source: SeekingAlpha
Date: July, 05 2017 08:02
Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
Bionomics Invited to PTSD State of the Science Summit to Present Key BNC210 Data
Source: OTC Markets
Date: June, 15 2017 00:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-190.47740.4750.47740.4755,000
2018-04-180.4850.4850.4850.47532,000
2018-04-170.4750.4750.4750.47510,157
2018-04-160.500.5050.510.49139,073
2018-04-150.480.480.4850.478150,114

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-04-191,0005,00020.0000Cover
2018-04-1822,00032,00068.7500Short
2018-04-16131,773139,07394.7510Short
2018-04-13149,599150,11499.6569Short
2018-04-111,4906,49022.9584Cover

* Short Mode

Short Analysis provided by Squeeze Report.


About Bionomics Ltd. (OTC: BNOEF)

Logo for Bionomics Ltd. (OTC: BNOEF)

Bionomics is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer.

 

Contact Information

 

 

Current Management

  • Deborah Rathjen / CEO
  • Jack Moschakis / Company Secretary
  • Errol De Souza / Chairman
  • Alan Fisher /
  • Deborah Rathjen /
  • Peter Turner /
  • David Wilson /

Current Share Structure

  • Market Cap: $186,515,450 - 03/16/2018
  • Authorized: 481,952,066 - 09/18/2017
  • Issue and Outstanding: 481,952,066 - 09/18/2017

 


Recent Filings from (OTC: BNOEF)

Semi-Annual Report - Half Yearly Report and Accounts
Filing Type: Semi-Annual Report - Half Yearly Report and AccountsFiling Source: OTC Markets
Filing Date: February, 13 2018
Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: January, 31 2018
Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: October, 31 2017
Proxy Materials - Notice of Annual General Meeting/Proxy Form
Filing Type: Proxy Materials - Notice of Annual General Meeting/Proxy FormFiling Source: OTC Markets
Filing Date: October, 13 2017
Annual Report - Bionomics Annual Report 2017
Filing Type: Annual Report - Bionomics Annual Report 2017Filing Source: OTC Markets
Filing Date: October, 13 2017
Preliminary Results - Appendix 4E - Full Year Statutory Accounts
Filing Type: Preliminary Results - Appendix 4E - Full Year Statutory AccountsFiling Source: OTC Markets
Filing Date: August, 21 2017
Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: August, 07 2017
Quarterly Report - Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: April, 26 2017
Semi-Annual Report - Half Yearly Report and Accounts
Filing Type: Semi-Annual Report - Half Yearly Report and AccountsFiling Source: OTC Markets
Filing Date: February, 21 2017
Quarterly Report - Appendix 4C - quarterly
Filing Type: Quarterly Report - Appendix 4C - quarterlyFiling Source: OTC Markets
Filing Date: February, 01 2017

 

 


Daily Technical Chart for (OTC: BNOEF)

Daily Technical Chart for (OTC: BNOEF)


Stay tuned for daily updates and more on (OTC: BNOEF)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BNOEF)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BNOEF is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BNOEF and does not buy, sell, or trade any shares of BNOEF. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us